Arena Pharmaceuticals Inc. (Nasdaq: ARNA) reported positive results from a Phase 2 OASIS trial for etrasimod to treat ulcerative colitis. Shares of the biopharmaceutical leaped $8.86 to close at $39.75.
Advertisement
August 12: "Get Retrofit: Insurance Savings from Property Upgrades"
August 7: "Friends & Foes: Best Practices for Social Media Risk Management"
August 17: "Supply Chain Crisis?Navigating Business Interruption Coverage and Claims After the Japanese Earthquakes"
September 8: "Dormant Dangers: Protecting Key Corporate Assets from Cyber Attacks"
Advertisement
Aug. 22/29: Industry Financials: First-Half Results
Health Care Reform: Impact on Firms
September 5: Special Report: Alternative Risks
September 12: Workers Comp & Safety Management
Advertisement
Advertisement
Advertisement